← 11 October 2026's Current Affairs · Karnataka KPSC Prelims ★★★★☆ Mains ★★☆☆☆
Karnataka seeks wider price caps on high-cost life-saving drugs
સમાચારમાં કેમ?
Who actually fixes medicine prices? The NPPA and DPCO answer Prelims tests, and Karnataka wants it widened
Karnataka Health Minister U.T.
Why it matters: factual, Prelims-type; Karnataka-specific
What you need to know
2 મિનિટ
Karnataka Health Minister U.T.
Khader said the State is seeking price caps beyond cancer medicines on other high-cost life-saving drugs.
He said price rationalisation should translate into direct savings for patients and not just lower margins.
The State also reported that some private hospitals are refusing treatment under the Arogya Karnataka scheme.
સ્રોત: Topper IAS editorial (PIB / The Hindu / Indian Express)
મુખ્ય તથ્યો
Remember these
- Karnataka Health Minister U.T. Khader said the State wants price caps extended beyond cancer medicines to other high-cost life-saving drugs.
- The National Pharmaceutical Pricing Authority (NPPA) fixes and revises ceiling prices of scheduled medicines under the Drugs (Prices Control) Order, 2013.
- Karnataka argues that price rationalisation must give patients direct savings, not merely lower trade margins.
- Some private hospitals are reported to be refusing treatment under the Arogya Karnataka scheme.
- CDSCO, headed by the DCGI, regulates drug approvals and quality, not prices.
પ્રિલિમ્સ · મેઇન્સ
How the exam will ask it
પ્રિલિમ્સ
- The National Pharmaceutical Pricing Authority fixes and revises ceiling prices of scheduled drugs under the Drugs (Prices Control) Order, 2013.
- CDSCO, headed by the Drugs Controller General of India, regulates the approval and quality of drugs; it does not set ceiling prices.
- Arogya Karnataka is the State's health assurance scheme; empanelled private hospitals provide treatment under it.
- Drug price control is exercised through the Essential Commodities Act, 1955, with scheduled drugs drawn from the National List of Essential Medicines.
મેઇન્સ
GS-2 (health, federalism, welfare schemes) and GS-3 (pharma sector). Issue: high costs of life-saving drugs and private hospitals refusing scheme patients. Provision: NPPA ceiling prices under the DPCO, 2013 and Arogya Karnataka empanelment. Implication: unless trade-margin cuts reach patients and hospitals comply, out-of-pocket expenditure persists. Way forward: wider price caps, transparent monitoring, enforcement of empanelment terms and stronger Centre-State coordination.
Quick recall
Answer before you reveal
Ceiling prices of scheduled medicines in India are fixed by which authority under the Drugs (Prices Control) Order, 2013?
- Central Drugs Standard Control Organisation
- Indian Council of Medical Research
- Drugs Controller General of India
- National Pharmaceutical Pricing Authority
જવાબ જુઓ
જવાબ: D — Correct: National Pharmaceutical Pricing Authority — The National Pharmaceutical Pricing Authority fixes and revises ceiling prices of scheduled drugs under the DPCO, the mechanism Karnataka wants extended. • Central Drugs Standard Control Organisation — wrong: CDSCO regulates drug approvals and quality, not ceiling prices. • Indian Council of Medical Research — wrong: ICMR is the apex body for biomedical research, not for pricing medicines. • Drugs Controller General of India — wrong: The DCGI heads CDSCO and regulates approvals, not price ceilings.
Convert this topic into marks
Today's 10-MCQ test · instant analysis · Powered by AdaptIQ